Vector Science & Therapeutics Chas entered an exclusive licensing and manufacturing agreement with LyoGenesis Plus, a cGMP lyophilisation and manufacturing partner based in Mequon, Wisconsin.
Under the agreement, Vector licenses its proprietary biomechanical peptide delivery platform to LyoGenesis, and in return secures an exclusive, long-term manufacturing relationship covering Vector’s proprietary peptide portfolio.
This agreement supersedes and renders null the company’s previously announced option to invest in LyoGenesis Plus. The new agreement replaces that option with a direct commercial arrangement: a technology license to LyoGenesis in exchange for exclusive manufacturing rights of Vector’s proprietary peptides.
Vector’s biomechanical delivery platform incorporates nanoscale carrier technology to enable targeted delivery of peptides directly to specific tissue sites, where the device releases the peptide precisely where it is needed. This targeted-release mechanism differentiates Vector’s peptide portfolio from conventional peptide therapeutics on the market today, giving Vector a suite of patent-protected peptides and a distinct competitive advantage in the rapidly evolving peptide therapeutics space.
Unlike research-grade material sold in the unregulated grey market which is often manufactured without cGMP controls and is legally required to be labelled ‘not for human use’ every peptide in Vector’s portfolio will be manufactured at LyoGenesis’ cGMP facility and tested for potency, purity, endotoxin levels, heavy metals, and sterility prior to release, meeting pharmaceutical-grade quality standards.
Vector’s proprietary peptide portfolio, which will be manufactured under the new agreement and distributed exclusively through physician and clinical channels, includes:
Under the agreement, LyoGenesis will develop Vector’s platform for commercial use, with all Vector peptides formulated at LyoGenesis’ Mequon, Wisconsin facility. The facility features onsite analytical capabilities to test potency, purity, endotoxin levels, heavy metals, and sterility ensuring every batch meets rigorous quality standards before release. Depending on demand, Vector and LyoGenesis estimates they will be able to scale production to satisfy up to 800,000 vials per month at with gross margins of up to 60-80-% per vial for pharma-grade, cGMP-manufactured product.
The agreement positions Vector to capture demand in a peptide therapeutics market projected to grow significantly to approximately US$185.3 billion by 2035, as adoption of peptide-based treatments for metabolic, oncologic, and regenerative applications continues to expand.
Within that space, the GLP-1 receptor agonist category which includes semaglutide and tirzepatide, both part of Vector’s portfolio, is the largest and fastest-growing segment, projected to grow from approximately US$82.0 billion in 2026 to US$185.3 billion by 2033, a CAGR of approximately 12.4%.
The licensing and manufacturing agreement strengthens Vector’s position across its broader peptide portfolio, including its Valor sports medicine division, by ensuring a dedicated, high-capacity, quality-controlled, physician-channel supply chain for its patent-protected peptide technologies as they advance toward commercialisation.
